tiprankstipranks
Trending News
More News >
Wuxi Biologics (Cayman) Inc. (WXIBF)
OTHER OTC:WXIBF
US Market

Wuxi Biologics (Cayman) (WXIBF) Income Statement

Compare
153 Followers

Wuxi Biologics (Cayman) Income Statement

Last quarter (Q2 2025), Wuxi Biologics (Cayman)'s total revenue was ¥9.95B, an increase of 17.21% from the same quarter last year. In Q2, Wuxi Biologics (Cayman)'s net income was ¥2.34B. See Wuxi Biologics (Cayman)’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
¥ 18.68B¥ 17.03B¥ 15.27B¥ 10.29B¥ 5.61B
Gross Profit
¥ 7.65B¥ 6.83B¥ 6.72B¥ 4.83B¥ 2.53B
Operating Expenses
¥ 2.68B¥ 2.38B¥ 2.38B¥ 1.64B¥ 771.43M
Depreciation and Amortization
¥ 1.44B¥ 1.17B¥ 800.67M¥ 481.78M¥ 303.01M
EBITDA
¥ 6.43B¥ 5.50B¥ 6.22B¥ 4.51B¥ 2.31B
Operating Income
¥ 4.97B¥ 4.45B¥ 4.34B¥ 3.19B¥ 1.50B
Other Income/Expenses
¥ -139.41M¥ -276.39M¥ 1.02B¥ 805.01M¥ 463.73M
Pretax Income
¥ 4.83B¥ 4.17B¥ 5.36B¥ 3.99B¥ 1.97B
Net Income
¥ 3.36B¥ 3.40B¥ 4.42B¥ 3.39B¥ 1.69B
Per Share Metrics
Basic EPS
¥ 0.82¥ 0.82¥ 1.06¥ 0.81¥ 0.43
Diluted EPS
¥ 0.78¥ 0.77¥ 1.01¥ 0.77¥ 0.40
Weighted Average Shares Outstanding
4.08B 4.16B 4.17B 4.40B 4.21B
Weighted Average Shares Outstanding (Diluted)
4.23B 4.35B 4.38B 4.42B 4.21B
Currency in CNY

Wuxi Biologics (Cayman) Earnings and Revenue History